Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 17;33(171):230156.
doi: 10.1183/16000617.0156-2023. Print 2024 Jan 31.

Pulmonary veno-occlusive disease: illustrative cases and literature review

Affiliations
Review

Pulmonary veno-occlusive disease: illustrative cases and literature review

Benoit Lechartier et al. Eur Respir Rev. .

Abstract

Pulmonary veno-occlusive disease (PVOD), also known as "pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement", is a rare cause of PAH characterised by substantial small pulmonary vein and capillary involvement, leading to increased pulmonary vascular resistance and right ventricular failure. Environmental risk factors have been associated with the development of PVOD, such as occupational exposure to organic solvents and chemotherapy, notably mitomycin. PVOD may also be associated with a mutation in the EIF2AK4 gene in heritable forms of disease. Distinguishing PVOD from PAH is critical for guiding appropriate management. Chest computed tomography typically displays interlobular septal thickening, ground-glass opacities and mediastinal lymphadenopathy. Life-threatening pulmonary oedema is a complication of pulmonary vasodilator therapy that can occur with any class of PAH drugs in PVOD. Early referral to a lung transplant centre is essential due to the poor response to therapy when compared with other forms of PAH. Histopathological analysis of lung explants reveals microvascular remodelling with typical fibrous veno-occlusive lesions. This review covers the main features distinguishing PVOD from PAH and two clinical cases that illustrate the challenges of PVOD management.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: B. Lechartier reports travel support from Janssen and advisory board participation with MSD, outside the submitted work. A. Boucly reports grants from Acceleron, Janssen and MSD; lecture honoraria from Janssen, MSD, AOP Orphan and Ferrer; and travel support from Janssen, MSD and Ferrer, outside the submitted work. D. Montani reports grants from Acceleron, Janssen and MSD; consulting fees from Acceleron, Merck MSD, Janssen and Ferrer; and lecture honoraria from Bayer, Janssen, Boehringer, Chiesi, GSK, Ferrer and Merck MSD, outside the submitted work. All other authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Computed tomography and histopathological images of patient 1 at diagnosis (2009) (a and b) and at the time of lung transplantation (2017) (c and d). a) In 2009, chest computed tomography revealed mild nonspecific ground-glass opacities and interlobular septal thickening, without lymph node enlargement (not shown). c) In 2017, ground-glass opacities and interlobular septal thickening are more pronounced. b) Lung histology in 2009 (surgical biopsy, haematoxylin and eosin staining) and d) in 2017 (lung transplant, haematoxylin and eosin–saffron staining) are shown. In b), pulmonary microcirculation (scale bar = 50 µm) shows extensive thickening of the intima (arrow) with subtle venous remodelling (asterisk). d) Subtotal obliteration of septal veins is confirmed in the explanted lung in 2017 (asterisk) with patchy capillary congestion and proliferation (arrow) and more extensive remodelling of the microcirculation (zoom-in panel; scale bar = 50 µm).
FIGURE 2
FIGURE 2
Computed tomography images of patient 2, a) at diagnosis and b) 2 weeks later.

Comment in

  • doi: 10.1183/16000617.0237-2023

References

    1. Montani D, Lau EM, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2016; 47: 1518–1534. doi: 10.1183/13993003.00026-2016 - DOI - PubMed
    1. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964–1973. doi: 10.1164/ajrccm.162.5.9912045 - DOI - PubMed
    1. Montani D, Price LC, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189–200. doi: 10.1183/09031936.00090608 - DOI - PubMed
    1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618–3731. doi: 10.1093/eurheartj/ehac237 - DOI - PubMed
    1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. doi: 10.1183/13993003.01913-2018 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources